Kato Hideo, Hagihara Mao, Morikawa Yoshihiko, Asai Nobuhiro, Mikamo Hiroshige, Iwamoto Takuya
Department of Pharmacy, Mie University Hospital, Tsu 514-8507, Japan.
Department of Clinical Pharmaceutics, Division of Clinical Medical Science, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.
Antibiotics (Basel). 2022 Jul 22;11(8):983. doi: 10.3390/antibiotics11080983.
Although a 2 g once daily administration of ceftriaxone remains the standard dosing regimen for the treatment of aspiration pneumonia, there are no studies to investigate the optimal dosing method. Hence, we retrospectively evaluated the effectiveness and safety of 1 g twice daily versus 2 g once daily administration of ceftriaxone in adult patients with aspiration pneumonia. Patients who received ceftriaxone for the treatment of aspiration pneumonia between 2015 and 2021 were included in this study. Clinical responses, inflammatory markers, and incidence of adverse events after completion of ceftriaxone therapy were investigated. In total, 33 patients received 1 g twice daily (group 1) and 28 received 2 g once daily (group 2) ceftriaxone for the treatment of mild-to-moderate aspiration pneumonia. Compared with that of group 1, group 2 demonstrated significantly improved clinical responses (group 1 vs. group 2, 84.8% vs. 100%, = 0.0316). Although the safety profile was not significantly different between the two groups, the incidence of choleliths during ceftriaxone therapy in group 1 was higher than that in group 2 (31.3% vs. 9.1%, = 0.174). Therefore, a 2 g once daily administration of ceftriaxone appeared to be a simple regimen adequate for the treatment of inpatients with mild-to-moderate aspiration pneumonia, which might not be heavily involved by anaerobes.
尽管每日一次给予2克头孢曲松仍然是治疗吸入性肺炎的标准给药方案，但尚无研究探讨最佳给药方法。因此，我们回顾性评估了每日两次给予1克与每日一次给予2克头孢曲松治疗成人吸入性肺炎的有效性和安全性。本研究纳入了2015年至2021年间接受头孢曲松治疗吸入性肺炎的患者。研究了头孢曲松治疗结束后的临床反应、炎症标志物和不良事件发生率。共有33例患者接受每日两次1克（第1组）和28例接受每日一次2克（第2组）头孢曲松治疗轻度至中度吸入性肺炎。与第1组相比，第2组的临床反应显著改善（第1组与第2组，84.8%对100%，P = 0.0316）。虽然两组的安全性概况无显著差异，但第1组头孢曲松治疗期间胆结石的发生率高于第2组（31.3%对9.1%，P = 0.174）。因此，每日一次给予2克头孢曲松似乎是一种简单的方案，足以治疗轻度至中度吸入性肺炎的住院患者，这类患者可能未受到厌氧菌的严重影响。
